Skip to main content

Table 2 CCND3 rs2479717 genotype frequency across stage, grade, and estrogen receptor status

From: Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort

  CCND3 rs2479717 genotype
  AA AT TT Missing
Stage     
   1 1,193 (54.5%) 808 (36.9%) 142 (6.5%) 48 (2.2%)
   2 1,031 (52.0%) 753 (38.0%) 145 (7.3%) 54 (2.7%)
   3 or 4 90 (46.4%) 82 (42.3%) 17 (8.8%) 5 (2.6%)
   Missing 60 (58.8%) 31 (30.4%) 9 (8.8%) 2 (2.0%)
Grade     
   1 484 (55.4%) 314 (35.9%) 60 (6.9%) 16 (1.8%)
   2 889 (52.7%) 658 (39.0%) 104 (6.2%) 36 (2.1%)
   3 533 (52.3%) 375 (36.8%) 86 (8.4%) 26 (2.5%)
   Missing 468 (52.5%) 327 (36.7%) 63 (7.1%) 34 (3.8%)
Estrogen receptor status     
   Positive 1,089 (55.1%) 717 (36.3%) 130 (6.6%) 39 (2.0%)
   Negative 320 (49.3%) 262 (40.4%) 53 (8.2%) 14 (2.2%)
   Missing 965 (52.3%) 695 (37.6%) 130 (7.0%) 56 (3.0%)